The Future of Biology is Computational.
We accelerate the $16.4B Antibody and Reagents Market using AI-driven precision to create nanobodies.
The Revolution: Legacy vs. AI Nanobodies
This highly visual comparison immediately demonstrates why Ziab is faster, cheaper, and more precise than the traditional, animal-based processes used by competitors.
Traditional Antibody Development: Slow, Costly, Animal-Based
Animal Injection
Target antigen injected into an animal (e.g., cow, camel).
Blood Extraction
Blood collected, B-cells isolated over weeks/months.
Cloning & Screening
Manual, resource-intensive process of testing clones.
Ziab's AI-Driven Nano body Development: Fast, Precise, Cost-Efficient
Computational Design
AI demystifies target structure to design optimal nanobody candidates.
Rapid Synthesis & Screening
Digital selection and production of candidates in weeks.
Optimized Final Product
Superior stability and specificity for complex targets.
Core Financials & Unique Selling Points
First Pass
Success Rate
Faster Discovery
Timeline
Specific Target
Market
Unique Selling Points
AI-Designed,
Not Discovered
Our computational approach guarantees optimal candidate design, eliminating resource-intensive screening.
1/10th Size, Maximum Penetration
Nanobodies penetrate deeper into tissues and target complex structures (e.g., Blood-Brain Barrier).
De-Risking Customer Pipelines
High stability and specificity reduce failure rates, saving customers time and millions in downstream R&D costs.
Data Velocity, Efficiency, and Return
The Nano body market is accelerating at 13.5% CAGR, significantly outpacing the mature Monoclonal Antibody market (7.8% CAGR)
Market Velocity: Nanobody Growth (CAGR)
Nanobody market CAGR: 13.5%; mAb market CAGR: 7.8%
Problem & Solution Overview
Slow Development
Traditional methods are slow, failing to meet the pace of computational biology.
Acceleration
Ziab's AI pipeline accelerates development 10x, enabling rapid market entry.
Manual Inefficiency
High cost and low success rate of manual development deter innovation.
Automation Efficiency
Computational design ensures a higher success rate and optimized production costs.
Limited Penetration
Legacy mAbs struggle with complex targets (e.g., blood-brain barrier penetration).
Nanobody Reach
Nanobodies' small size provides superior access to difficult biological targets.
Market Applications
Immunology
12.5% CAGR
Traditional methods are slow, failing to meet the pace of computational biology.
Neuroscience
9.8% CAGR
Key for blood-brain barrier penetration research.
ImmunoOncology
12.5% CAGR
Largest growth area, essential for next-gen therapeutics.
Oncology
12.5% CAGR
Core market segment for targeted therapy development.